Clinical trials: Metastatic Breastcancer
Metastatic Breast Cancer, Metastatic Breast Cancer (MBC)
Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients
The purpose of this study is to examine which of four components of a digital health intervention using an App and Fitbit meaningfully contribute to increased physical activity in Metastatic Breast Cancer Patients.
- Conditions
- Metastatic Breast Cancer, Metastatic Breast Cancer (MBC), Metastatic Breastcancer
- Trial name
- Fit2ThriveMB (NCT07840599)
- Testing
- Core Intervention, EHR Integration (On v. Off), Weekly Coaching
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Northwestern University
Metastatic Breastcancer
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Longer first line chemotherapy duration has recently been associated with a modest, but significant improvement in overall survival and a clinically meaningful and statistically significant improvement in progression-free…
- Trial name
- SNAP (NCT01746225)
- Testing
- nab-Paclitaxel
- Where
- 41 sites in Belgium, Ireland and 4 more
- Volunteers
- 258 people
- Sponsor
- ETOP IBCSG Partners Foundation
Metastatic Breastcancer
Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers
Whole-body MRI including diffusion is a booming technique. Numerous studies have demonstrated its interest in metastatic cancers.
- Trial name
- NCT02966574
- Testing
- whole body MRI
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Brugmann University Hospital
Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Diffuse large B-cell lymphomas (DLBCLs) represent 25 to 30% of adult non-Hodgkin lymphomas in western countries. DLBCLs are aggressive cancer but potentially curable with multi-agent chemotherapy.
- Conditions
- Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma, Metastatic Breastcancer, Non-small Cell Lung Cancer
- Trial name
- BMS_PD-L1 (NCT01660776)
- Where
- 4 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Metastatic Breastcancer
Advanced Breast Cancer and Lifestyle Exercise Study
About 5% of breast cancers are metastatic at diagnosis and 20-30% of localized breast cancer become secondarily metastatic.Thanks to recent therapeutic advances, the median survival ranges between 12 months in 1970 and 18 to 24…
- Trial name
- ABLE (NCT03148886)
- Testing
- PA intervention
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Centre Leon Berard
Metastatic Breastcancer
Effect of a Mentor-based, Supportive-expressive Program on Survival in Metastatic Breast Cancer
Breast cancer is the most prevalent cancer in women and annually accounts for 10% of new malignancies worldwide. In mainland China, approximately 169,000 females are diagnosed with breast cancer every year and constitute 12.25%…
- Trial name
- NCT03026374
- Testing
- Be Resilient to Breast Cancer
- Where
- China
- Volunteers
- 204 people
- Sponsor
- The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated postmenopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast…
- Conditions
- Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer, Estrogen Receptor Negative Neoplasm, Progesterone Receptor Positive Tumor
- Trial name
- ARTT (NCT02000375)
- Testing
- DHEA
- Where
- 8 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS